Leadership changes at A3P Biomedical
A3P Biomedical (“A3P”) today announces that Chief Executive Officer (“CEO”) David Rosén is leaving his position to pursue other opportunities outside the Group. Executive Chairman Martin Steinberg will lead the company from June 1, with Ola Steinberg as CEO until the appointment of a new CEO.
“The Board extends its gratitude to David for his valuable contribution to A3P over the past three years as the company’s CEO. His efforts in building the internal infrastructure and strengthening the team has established a robust foundation for accelerated business expansion. We wish him all the best in his future endeavors,” says Martin Steinberg, Chairman of the Board.
With market presence in Switzerland, Germany, and the USA, A3P is entering a new phase. The focus is to expand the business in these and other markets by establishing partnerships and alliances, driving sales, attracting sales and marketing talent, all with the aim of establishing Stockholm3 as the standard of care for early detection of aggressive prostate cancer.
“As we enter the next phase of our growth journey, we are rapidly moving towards a SaaS model both in Europe and the USA, which places high and partly new demands on us. Succeeding in the USA is of the highest priority. Therefore, we will be seeking a CEO with a proven track record and experience in driving accelerated international expansion within life science – to take us to the next level,” Martin Steinberg concludes.
For additional information, please contact:
Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com
About A3P Biomedical
A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 90,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood test that combines protein biomarkers, genetic biomarkers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces unnecessary biopsies by 50 percent compared to current practice with PSA (1).
Stockholm3 has been evaluated in clinical studies with more than 90,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) “Prostate Cancer Research Award 2022”. Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).
Based on robust peer-reviewed clinical data, leading Nordic healthcare providers have replaced PSA with Stockholm3. Region Värmland in Sweden has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75, who benefit from a more precise test with increased sensitivity and specificity. At the same time, healthcare providers can reduce direct costs by 17 to 28 percent (1).
(1) Publications, results and clinical validation.
About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.